PULMOKINE, INC.

Address

PULMOKINE, INC.
68 QUEEN ANNE DR
SLINGERLANDS, NY, 12159-9385

http://www.pulmokine.net

Information

DUNS: 808479906
# of Employees: 4

Ownership Information

Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N

Award Charts




Award Listing

  1. A phosphopeptide multiplex PRM mass spectroscopic biomarker assay for PAH

    Amount: $515,573.00

    The purpose of this phase SBIR grant is to develop a quantitative phosphopeptide biomarker assay for pulmonary arterial hypertension PAH The commercial product will consist of a kit of stable iso ...

    SBIRPhase I2017Department of Health and Human Services National Institutes of Health
  2. A novel inhaled c-kit/PDGFR inhibitor for the treatment of asthma

    Amount: $337,324.00

    DESCRIPTION provided by applicant The purpose of this project is to develop an inhaled combined c kit PDGFR inhibitor as a treatment for asthma Asthma is a chronic inflammatory disease characteri ...

    SBIRPhase I2016Department of Health and Human Services
  3. An inhaled PDGF receptor inhibitor for the treatment of pulmonary arterial hypertension

    Amount: $2,004,380.00

    DESCRIPTION provided by applicant Pulmokine is developing a novel inhaled PDGF receptor PDGFR kinase inhibitor PK as a treatment for Pulmonary Arterial Hypertension PAH The purpose of th ...

    SBIRPhase II2015Department of Health and Human Services
  4. IGF::OT::IGF Aerosolized Delivery of Anti-Tubercular Drugs

    Amount: $224,960.00

    Develop an inexpensive, easy to use, aerosolized delivery system of a combination of anti-tubercular drugs that could be used for the treatment of multi-drug resistant tuberculosis (MDR TB ). PUBLIC H ...

    SBIRPhase I2013Department of Health and Human Services
  5. An inhaled PDGF receptor inhibitor for the treatment of pulmonary arterial hyper

    Amount: $2,267,504.00

    DESCRIPTION (provided by applicant): The purpose of this Phase II project is to develop a new treatment for pulmonary arterial hypertension (PAH) consisting of the inhaled platelet derived growth fact ...

    SBIRPhase II2012Department of Health and Human Services
  6. A novel JAK inhibitor for the treatment of pulmonary arterial hypertension

    Amount: $311,629.00

    DESCRIPTION (provided by applicant): Pulmonary arterial hypertension (PAH) is a rare disease associated with high morbidity and mortality. The purpose of this proposal is to develop a novel combined J ...

    SBIRPhase I2010Department of Health and Human Services
  7. A PDGFR inhibitor for the treatment of pulmonary arterial hypertension

    Amount: $351,008.00

    DESCRIPTION (provided by applicant): Pulmonary arterial hypertension (PAH) is a devastating disease associated with high morbidity and mortality. The purpose of this proposal is to develop a novel hig ...

    SBIRPhase I2010Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government